Targeting the PI3K signaling pathway in cancer therapy

Bibliography

• Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997;22:267-72
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44
   PubMed Web of Science ®Google Scholar
• Norris FA, Atkins RC, Majerus PW. The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type 2. Evidence for conserved alternative splicing in the 4-phosphatase family. J Biol Chem 1997;272:23859-64
   PubMedGoogle Scholar
• Hodgson MC, Shao LJ, Frolov A, Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 2011;71:572-82
   Google Scholar
• Gewinner C, Wang ZC, Richardson A, Evidence that inositol polyphosphate 4-phosphatase type 2 is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009;16:115-25
   PubMed Web of Science ®Google Scholar
• Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 2011;16:404-14
   PubMed Web of Science ®Google Scholar
• LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008;11:32-50
   PubMed Web of Science ®Google Scholar
• Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-90
   PubMed Web of Science ®Google Scholar
• Carver BS, Pandolfi PP. Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 2006;12:5305-11
   PubMed Web of Science ®Google Scholar
• Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-8
   PubMed Web of Science ®Google Scholar
• Risinger JI, Hayes K, Maxwell GL, PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005-10
   PubMed Web of Science ®Google Scholar
• Garcia JM, Silva JM, Dominguez G, Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 1999;57:237-43
   Google Scholar
• Yang J, Ren Y, Wang L, PTEN mutation spectrum in breast cancers and breast hyperplasia. J Cancer Res Clin Oncol 2010;136:1303-11
   Google Scholar
• Khan S, Kumagai T, Vora J, PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 2004;112:407-10
   Google Scholar
• Kwabi-Addo B, Giri D, Schmidt K, Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001;98:11563-8
   PubMed Web of Science ®Google Scholar
• Janku F, Lee JJ, Tsimberidou AM, PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLOS One 2011;7(6): published online 29 July 2011; doi:10.1371/journal.pone.0022769
   Google Scholar
• Kalinsky K, Jacks LM, Heguy A, PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009;15:5049-59
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Martini M, Molinari F, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-7
   PubMed Web of Science ®Google Scholar
• Arboleda MJ, Lyons JF, Kabbinavar FF, Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 2003;63:196-206
   PubMed Web of Science ®Google Scholar
• Irie HY, Pearline RV, Grueneberg D, Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 2005;171:1023-34
   PubMed Web of Science ®Google Scholar
• Carpten JD, Faber AL, Horn C, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44
   PubMed Web of Science ®Google Scholar
• Liby TA, Spyropoulos P, Buff Lindner H, Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells. Int J Cancer 2012;130:532-43
   PubMed Web of Science ®Google Scholar
• Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241-8
   PubMed Web of Science ®Google Scholar
• Powis G, Bonjouklian R, Berggren MM, Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 1994;54:2419-23
   PubMed Web of Science ®Google Scholar
• Ohwada J, Ebiike H, Kawada H, Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. Bioorg Med Chem Lett 2011;21:1767-72
   PubMed Web of Science ®Google Scholar
• Dan S, Yoshimi H, Okamura M, Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochem Biophys Res Commun 2009;379:104-9
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-67
   PubMed Web of Science ®Google Scholar
• Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28:727-32
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34
   PubMed Web of Science ®Google Scholar
• Fasolo A, Sessa C. Current and future directions in mammalian target of rapamycin inhibitors development. Expert Opin Investig Drugs 2011;20:381-94
   PubMed Web of Science ®Google Scholar
• Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008;17:1717-34
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6
   PubMed Web of Science ®Google Scholar
• Dan S, Okamura M, Seki M, Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res 2010;70:4982-94
   Google Scholar
• Wang SI, Puc J, Li J, Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-6
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-53
   PubMed Web of Science ®Google Scholar
• Teng DH, Hu R, Lin H, MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997;57:221-5225
   Google Scholar
• Li J, Yen C, Liaw D, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7
   PubMed Web of Science ®Google Scholar
• Blando J, Portis M, Benavides F, PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol 2009;174:1869-79
   PubMedGoogle Scholar
• Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003;22:3113-22
   PubMed Web of Science ®Google Scholar
• Wen YG, Wang Q, Zhou CZ, Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. Oncol Rep 2010;24:89-95
   Google Scholar
• Kanamori Y, Kigawa J, Itamochi H, Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 2001;7:892-5
   PubMed Web of Science ®Google Scholar
• Hayes MP, Wang H, Espinal-Witter R, PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006;12:5932-5
   PubMed Web of Science ®Google Scholar
• Kolasa IK, Rembiszewska A, Janiec-Jankowska A, PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol 2006;103:692-7
   PubMedGoogle Scholar
• Nassif NT, Lobo GP, Wu X, PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 2004;23:617-28
   PubMed Web of Science ®Google Scholar
• Hartmann C, Bartels G, Gehlhaar C, PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol 2005;109:639-42
   PubMed Web of Science ®Google Scholar
• Gallia GL, Rand V, Siu IM, PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 2006;4:709-14
   PubMed Web of Science ®Google Scholar
• Bachman KE, Argani P, Samuels Y, The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-5
   PubMed Web of Science ®Google Scholar
• Campbell IG, Russell SE, Choong DY, Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81
   PubMed Web of Science ®Google Scholar
• Miron A, Varadi M, Carrasco D, PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010;70:5674-8
   Google Scholar
• Levine DA, Bogomolniy F, Yee CJ, Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-8
   PubMed Web of Science ®Google Scholar
• Janku F, Tsimberidou AM, Garrido-Laguna I, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011;10:558-65
   PubMed Web of Science ®Google Scholar
• Lee JW, Soung YH, Kim SY, PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477-80
   PubMed Web of Science ®Google Scholar
• Sun X, Huang J, Homma T, Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res 2009;29:1739-43
   PubMed Web of Science ®Google Scholar
• Omholt K, Krockel D, Ringborg U, Hansson J. Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res 2006;16:197-200
   PubMed Web of Science ®Google Scholar
• Barbi S, Cataldo I, De Manzoni G, The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 2010;29:32
   PubMed Web of Science ®Google Scholar
• Velho S, Oliveira C, Ferreira A, The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41:1649-54
   PubMed Web of Science ®Google Scholar
• Catasus L, Gallardo A, Cuatrecasas M, Prat J. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 2008;21:131-9
   PubMed Web of Science ®Google Scholar
• Nosho K, Kawasaki T, Ohnishi M, PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008;10:534-41
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Shigematsu H, Nomura M, PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6913-21
   PubMed Web of Science ®Google Scholar
• Okudela K, Suzuki M, Kageyama S, PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007;57:664-71
   PubMed Web of Science ®Google Scholar
• Askham JM, Platt F, Chambers PA, AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2010;29:150-5
   PubMedGoogle Scholar
• Do H, Solomon B, Mitchell PL, Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes 2008;1:14
   PubMedGoogle Scholar
• Boormans JL, Korsten H, Ziel-van der Made AC, E17K substitution in AKT1 in prostate cancer. Br J Cancer 2010;102:1491-4
   PubMed Web of Science ®Google Scholar
• Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 2008;98:1533-5
   PubMed Web of Science ®Google Scholar
• Cohen Y, Shalmon B, Korach J, AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol Oncol 2010;116:88-91
   Web of Science ®Google Scholar
• Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987;84:5034-7
   PubMed Web of Science ®Google Scholar
• Ruggeri BA, Huang L, Wood M, Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 1998;21:81-6
   PubMed Web of Science ®Google Scholar
• Miwa W, Yasuda J, Murakami Y, Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem Biophys Res Commun 1996;225:968-74
   PubMedGoogle Scholar
• Cheng JQ, Ruggeri B, Klein WM, Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996;93:3636-41
   PubMed Web of Science ®Google Scholar
• Bellacosa A, de Feo D, Godwin AK, Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5
   PubMed Web of Science ®Google Scholar
• Xu X, Sakon M, Nagano H, Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep 2004;11:25-32
   PubMedGoogle Scholar
• Cheng JQ, Godwin AK, Bellacosa A, AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992;89:9267-71
   PubMed Web of Science ®Google Scholar
• Kirkegaard T, Witton CJ, Edwards J, Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology 2010;56:203-11
   PubMed Web of Science ®Google Scholar
• Stahl JM, Sharma A, Cheung M, Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64:7002-10
   PubMed Web of Science ®Google Scholar